BMS 986036

Drug Profile

BMS 986036

Alternative Names: ARX-618; BMS-986036; FGF-21 mimetic proteins - Ambrx/Merck; PEG-FGF21; Pegylated-fibroblast growth factor-21 - Ambrx/Bristol-Myers Squibb

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Ambrx
  • Developer Bristol-Myers Squibb
  • Class Fibroblast growth factors; Obesity therapies; Polyethylene glycols; Proteins
  • Mechanism of Action Fibroblast growth factor 21 agonists; Fibroblast growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fibrosis; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 01 Apr 2016 Bristol-Myers Squibb completes a phase II trial for Type 2 diabetes mellitus in USA and Canada (NCT02097277)
  • 01 Feb 2016 Phase-II clinical trials in Fibrosis in USA before Februray 2016 (Bristol-Myers Squibb 10-K; February 2016) (Bristol-Myers Squibb pipeline, January 2017).
  • 01 Jan 2016 Phase-I clinical trials in Fibrosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top